Accelerated Path to Cures

Accelerated Path to Cures PDF

Author: Josep Bassaganya-Riera

Publisher: Springer

Published: 2018-04-25

Total Pages: 82

ISBN-13: 3319732382

DOWNLOAD EBOOK →

Accelerated Path to Cures provides a transformative perspective on the power of combining advanced computational technologies, modeling, bioinformatics and machine learning approaches with nonclinical and clinical experimentation to accelerate drug development. This book discusses the application of advanced modeling technologies, from target identification and validation to nonclinical studies in animals to Phase 1-3 human clinical trials and post-approval monitoring, as alternative models of drug development. As a case of successful integration of computational modeling and drug development, we discuss the development of oral small molecule therapeutics for inflammatory bowel disease, from the application of docking studies to screening new chemical entities to the development of next-generation in silico human clinical trials from large-scale clinical data. Additionally, this book illustrates how modeling techniques, machine learning, and informatics can be utilized effectively at each stage of drug development to advance the progress towards predictive, preventive, personalized, precision medicine, and thus provide a successful framework for Path to Cures.

Accelerated Path to Cures

Accelerated Path to Cures PDF

Author: Josep Bassaganya-Riera

Publisher:

Published: 2018

Total Pages:

ISBN-13: 9783319732398

DOWNLOAD EBOOK →

Accelerated Path to Cures provides a transformative perspective on the power of combining advanced computational technologies, modeling, bioinformatics and machine learning approaches with nonclinical and clinical experimentation to accelerate drug development. This book discusses the application of advanced modeling technologies, from target identification and validation to nonclinical studies in animals to Phase 1-3 human clinical trials and post-approval monitoring, as alternative models of drug development. As a case of successful integration of computational modeling and drug development, we discuss the development of oral small molecule therapeutics for inflammatory bowel disease, from the application of docking studies to screening new chemical entities to the development of next-generation in silico human clinical trials from large-scale clinical data. Additionally, this book illustrates how modeling techniques, machine learning, and informatics can be utilized effectively at each stage of drug development to advance the progress towards predictive, preventive, personalized, precision medicine, and thus provide a successful framework for Path to Cures.

21st Century Cures

21st Century Cures PDF

Author: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health

Publisher:

Published: 2015

Total Pages: 192

ISBN-13:

DOWNLOAD EBOOK →

Second Generation Cell and Gene-Based Therapies

Second Generation Cell and Gene-Based Therapies PDF

Author: Alain Vertes

Publisher: Academic Press

Published: 2020-02-07

Total Pages: 846

ISBN-13: 0128120339

DOWNLOAD EBOOK →

Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalisation serves as the only volume to the market to bridge basic science, clinical therapy, technology development, and business in the field of cellular therapy/cytotherapy. After more than two decades of painstaking fundamental research, the concept of therapeutic cells (stem cells, genes, etc.), beyond the concept of vaccines, is reaching clinical trial, with mounting confidence in the safety and efficacy of these products. Nonetheless, numerous incremental technical advances remain to be achieved. Thus, this volume highlights the possible R&D paths, which will ultimately facilitate clinical delivery of cutting edge curative products. The next waves of innovation are reviewed in depth for hematopoietic stem cells, mesenchymal stem cells, tissue engineering, CAR-T cells, and cells of the immune system, as well as for enabling technologies such as gene and genome editing. Additionally, deep dives in product fundamentals, history of science, pathobiology of diseases, scientific and technological bases, and financing and technology adoption constraints are taken to unravel what will shape the cytotherapy industry to the horizon 2025 and beyond. The outcome is not simply a scientific book, but a global perspective on the nascent field combining science, business, and strategic fundamentals. Helps readers learn about the most current trends in cell-based therapy, their overall effectiveness from a clinical prospective, and how the industry is moving therapies forward for capitalization "Perspectives" section at the end of each chapter summarizes key learnings, hypotheses, and objectives highlighted and combines scientific and business insights Edited and authored by scientists representing both basic and clinical research and industry, presenting a complete story of the current state and future promise of cellular therapies

Transfusion Medicine, An Issue of Hematology/Oncology Clinics of North America

Transfusion Medicine, An Issue of Hematology/Oncology Clinics of North America PDF

Author: Edward L Snyder

Publisher: Elsevier Health Sciences

Published: 2019-09-03

Total Pages: 193

ISBN-13: 0323709079

DOWNLOAD EBOOK →

This issue of Hematology/Oncology Clinics, Guest Edited by Drs. Edward Snyder and Eric A. Gehrie, with Consulting Editors George P. Canellos and H. Franklin Bunn, will focus on Transfusion Medicine. Topics include, but are not limited to, Pathogen Reduction, Transfusion Reactions-Infectious Complications, Txn Rxn-Non-Infectious Complications, Iron Deficiency and Teen Blood Donors, Advances in RBC Serology, Advances in Immunotherapy, Therapeutic Monoclonal Antibody Effect on RBC Compatibility Testing, Cell Therapy-New Regulations and Standards, Alternatives to Platelet and RBC Transfusions, New Hemostatic Agents, Tx Practices for Children with Cancer, and Relevance of Cold Platelets and WB to the Bleeding Oncology Patient.

Laser-Driven Particle Acceleration Towards Radiobiology and Medicine

Laser-Driven Particle Acceleration Towards Radiobiology and Medicine PDF

Author: Antonio Giulietti

Publisher: Springer

Published: 2016-05-04

Total Pages: 320

ISBN-13: 3319315633

DOWNLOAD EBOOK →

This book deals with the new method of laser-driven acceleration for application to radiation biophysics and medicine. It provides multidisciplinary contributions from world leading scientist in order to assess the state of the art of innovative tools for radiation biology research and medical applications of ionizing radiation. The book contains insightful contributions on highly topical aspects of spatio-temporal radiation biophysics, evolving over several orders of magnitude, typically from femtosecond and sub-micrometer scales. Particular attention is devoted to the emerging technology of laser-driven particle accelerators and their application to spatio-temporal radiation biology and medical physics, customization of non-conventional and selective radiotherapy and optimized radioprotection protocols.

The Cure in the Code

The Cure in the Code PDF

Author: Peter W. Huber

Publisher: Basic Books

Published: 2013-11-12

Total Pages: 304

ISBN-13: 0465069819

DOWNLOAD EBOOK →

Never before have two revolutions with so much potential to save and prolong human life occurred simultaneously. The converging, synergistic power of the biochemical and digital revolutions now allows us to read every letter of life's code, create precisely targeted drugs to control it, and tailor their use to individual patients. Cancer, diabetes, Alzheimer's and countless other killers can be vanquished—if we make full use of the tools of modern drug design and allow doctors the use of modern data gathering and analytical tools when prescribing drugs to their patients. But Washington stands in the way, clinging to outdated drug-approval protocols developed decades ago during medicine's long battle with the infectious epidemics of the past. Peter Huber, an expert in science, technology, and public policy, demonstrates why Washington's one-size-fits-all drug policies can't deal with diseases rooted in the complex molecular diversity of human bodies. Washington is ill-equipped to handle the torrents of data that now propel the advance of molecular medicine and is reluctant to embrace the statistical methods of the digital age that can. Obsolete economic policies, often rationalized as cost-saving measures, stifle innovation and suppress investment in the medicine that can provide the best cures at the lowest cost. In the 1980s, an AIDS diagnosis was a death sentence, until the FDA loosened its throttling grip and began streamlining and accelerating approval of life-saving drugs. The Cure in the Code shows patients, doctors, investors, and policy makers what we must now do to capture the full life-saving and cost-saving potential of the revolution in molecular medicine. America has to choose. At stake for America is the power to lead the world in mastering the most free, fecund, competitive, dynamic, and intelligent natural resource on the planet—the molecular code that spawns human life and controls our health.

Navigating the Manufacturing Process and Ensuring the Quality of Regenerative Medicine Therapies

Navigating the Manufacturing Process and Ensuring the Quality of Regenerative Medicine Therapies PDF

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2018-01-29

Total Pages: 125

ISBN-13: 0309466474

DOWNLOAD EBOOK →

On June 26, 2017, the Forum on Regenerative Medicine hosted a public workshop in Washington, DC, titled Navigating the Manufacturing Process and Ensuring the Quality of Regenerative Medicine Therapies in order to examine and discuss the challenges, opportunities, and best practices associated with defining and measuring the quality of cell and tissue products and raw materials in the research and manufacturing of regenerative medicine therapies. The goal of the workshop was to learn from existing examples of the manufacturing of early-generation regenerative medicine products and to address how progress could be made in identifying and measuring critical quality attributes. The workshop also addressed the challenges of designing and adhering to standards as a way of helping those who are working to scale up processes and techniques from a research laboratory to the manufacturing environment. This publication summarizes the presentations and discussions from the workshop.